Pharma BD Deal Intelligence

Watson Pharmaceuticals, Inc. / Specifar Pharmaceuticals S.A.

2011 · Acquisition/Merger · $562M · Complete

Announcement Sentiment

Strongly positive

Watson acquired Greek branded-generics developer Specifar for €400M (~$562M) cash plus contingent consideration of up to €40M (~$56M) tied to esomeprazole profits. Closed May 25, 2011. Strengthened Watson's European generics platform.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced May 02, 2011
Closed May 25, 2011
Deal value $562M
Deal type Acquisition/Merger
Therapeutic area Generic pharmaceuticals (multiple TAs)
Indications Generic pharmaceuticals (multiple TAs)
Key assets Generic esomeprazole and EU branded-generics portfolio
Mechanism Generic small-molecule formulations including esomeprazole (PPI)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals